Navigation Links
Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
Date:10/22/2013

e idiopathic type, the treatment of acute exacerbations of multiple sclerosis (MS) in adults, the treatment of infantile spasms (IS) in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to NS, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intention to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis.  The FDA-approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases".  Questcor is also exploring the possibility of developing markets for other FDA-approved indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "ensuring," "estimates," "expects," "growth," "may," "momentum," "plans," "potential," "remain," "should," "start," "substantial," "sustainable" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
2. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
3. Questcor to Commence Phase 2 Study of Acthar for ALS
4. Questcor to Report Second Quarter Financial Results on July 30, 2013
5. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
6. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
7. Questcor Adds Angus C. Russell to Board of Directors
8. Questcor Reports First Quarter Financial Results
9. Questcor to Report First Quarter Results on April 30, 2013
10. Questcor Reports Fourth Quarter and Full Year 2012 Results
11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... WHIPPANY, N.J. , March 4, 2015 /PRNewswire/ ... and Drug Administration (FDA) has accepted the company,s ... recombinant Factor VIII compound.  Bayer is seeking FDA ... Kovaltry™, for the treatment of hemophilia A in ... committed to continually bringing new therapies to hemophilia ...
(Date:3/4/2015)... , March 4, 2015  Heska Corporation (Nasdaq: ... Invites You to Join Its Fourth Quarter and Year ... 5, 2015 @ 9:00 a.m. (MST) / 11:00 a.m. ... End 2014 Earnings Call link on the front page ... on to the web at the address above.  Alternatively, ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Negative Pressure Wound Therapy Market (Conventional and ... Size, Share, Growth, Trends and Forecast 2014 - ... The global negative pressure wound therapy ... geography. By product types the NPWT market is ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2
... , PLEASANTON, Calif. , Jan. ... world leader in device-based mechanical circulatory support (MCS) therapies to ... has acquired an innovative catheter pump technology that it plans ... cardiac axial flow pump that can be delivered percutaneously in ...
... , HOUSTON , Jan. 25 ... peacefully in his home on January 19th after ... Woodyard began his tenure at eCardio as Vice President, Business ... development initiatives. He was also responsible for identifying, negotiating and ...
Cached Medicine Technology:Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology 2Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology 3Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology 4Richard Woodyard, Vice President of Sales at eCardio, Loses Fight Against Cancer 2
(Date:3/4/2015)... March 04, 2015 FDA’s New Inspection ... **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. – ... generally know within four hours of an inspection whether ... is on their “good” list, they’ll merely ask for ... manufacturer is on the “bad” list, the manufacturer must ...
(Date:3/4/2015)... Concord, NH (PRWEB) March 04, 2015 ... the natural frozen food category, will attend this year’s ... from its newest product line. With this new line, ... meals in the natural channel, continues its commitment to ... the fastest growing frozen brand in the natural channel, ...
(Date:3/4/2015)... 04, 2015 The print component of ... San Francisco Chronicle with a circulation of approximately 173,000 ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... Milorganite is composed of heat-dried microbes that have digested ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The New ... and lyrical music, will be performed by the award-winning ... Estates, CA, this March 6-22, 2015, on Fridays, Saturdays ... at Peninsula High School (27118 Silver Spur Road, ... hour before the program or may be purchased on-line ...
(Date:3/4/2015)... Columbus is no stranger to drug addiction. The ... addiction, and suffers from the potential threat of Kratom. In ... DEA revealed that Kratom is a “drug of concern.” Although ... introduced herb from Southeast Asia acts as a stimulant in ... kratom foments symptoms similar to heroin withdrawal, and includes tremors, ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2
... , BATESVILLE, Ind., and ANDOVER, Mass., Sept. ... strategic partnership agreement to integrate the Radianse real-time location system ... this move, Hill-Rom intends to extend its leadership in health ... obstacles for health care customers as they consider high-precision, enterprise-wide ...
... ... Association (DIA) Study Endpoints Special Interest Area Community (SIAC) will host Measuring Study Endpoints ... Caregiver from October 26-27, 2009 in New Orleans, LA. , ... Horsham, PA (Vocus) September 2, 2009 ...
... Sept. 2 The following is an updated GlaxoSmithKline Consumer Healthcare statement ... orlistat: , , On August 24th the FDA ... serious adverse events. , , To view the Multimedia ... It,s important consumers know that alli is safe and effective ...
... , , , ... Sept. 2 /PRNewswire-FirstCall/ -- ... that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other ... Doman, President and Chief Executive Officer, will present a corporate overview ...
... on their calls , TUESDAY, Sept. 1 (HealthDay ... research suggests they can appreciate music inspired by the ... similar to soothing monkey calls, the animals moved less ... distress calls, they became anxious. , This may not ...
... N.C., Sept. 2 Anpath Group, Inc. (OTC Bulletin Board: ANPG), ... joined the Board of Directors. , , Dr. ... care, specifically with HIV treatment and immunology. Currently he is ... Academy of HIV Medicine. In 2000, he founded his current ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 3Health News:Video: FDA States Consumers Should Continue to Use alli 2Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Scientists Make Sweet Monkey Music 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 3
... HeartMate II Left Ventricular Assist System (LVAS) ... shown to restore hemodynamic function and improve ... the rotary action of a single-moving part, ... full circulatory support by pumping blood from ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
... standard to extra-wide wheelchairs (18" to 43") ... heavy-duty, anodized aluminum weighing platform is equipped ... easy access for large patients. Weight is ... readout. The 6772 has the unique features ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
Medicine Products: